Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028740 · ClinicalTrials.gov registry record · Phase 3
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 3 study, sponsored by Tobira Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,778
- Enrollment target
NCT03028740 is a Phase 3 study that was terminated before completion, run by Tobira Therapeutics. The registered enrollment target is 1,778 participants.
The verdict
NCT03028740, a Phase 3 study, was terminated before completion, sponsored by Tobira Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,778 participants
- Enrollment target
Study Summary
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
Interventions
- DRUG Placebo
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,778 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028740
The ClinicalTrials.gov registry entry for NCT03028740 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03028740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028740 about?
NCT03028740 is a clinical study titled "AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)". The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
What is the current status of trial NCT03028740?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,778 participants. The study started on 2017-04-05. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT03028740?
The interventions under investigation include: Placebo (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT03028740?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.